Noborio-Hatano, K <br/><br/>
Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma.  [electronic resource] 

 -  Oncogene  Jan 2009 
 - 231-42 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1476-5594 
<br/><br/><label>Standard No.: </label>10.1038/onc.2008.385  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibodies--pharmacology<br/>Antineoplastic Agents--pharmacology<br/>Apoptosis--drug effects<br/>Boronic Acids--pharmacology<br/>Bortezomib<br/>Cell Adhesion--physiology<br/>Cell Adhesion Molecules--physiology<br/>Cell Line, Tumor--metabolism<br/>Dexamethasone--pharmacology<br/>Down-Regulation<br/>Doxorubicin--pharmacology<br/>Drug Resistance, Neoplasm--drug effects<br/>Gene Expression Regulation, Neoplastic--drug effects<br/>Gene Knockdown Techniques<br/>Humans<br/>Integrin alpha Chains--biosynthesis<br/>Integrin alpha4--biosynthesis<br/>Integrin alpha4beta1--physiology<br/>Multiple Myeloma--drug therapy<br/>Neoplasm Proteins--biosynthesis<br/>Pyrazines--pharmacology<br/>Vincristine--pharmacology